Efficacy and Safety of Risankizumab for Active Psoriatic Arthritis: 100-Week Results from the KEEPsAKE 2 Randomized Clinical Trial

Abstract Introduction Long-term therapeutic options providing durable response and tolerability are needed for psoriatic arthritis (PsA). The ongoing KEEPsAKE 2 trial is evaluating risankizumab treatment in patients with active PsA who previously had inadequate response/intolerance to ≥ 1 convention...

ver descrição completa

Detalhes bibliográficos

Principais autores:	Andrew Östör, Filip Van den Bosch, Kim Papp, Cecilia Asnal, Ricardo Blanco, Jacob Aelion, Kyle Carter, Vassilis Stakias, Ralph Lippe, Leonidas Drogaris, Ahmed M. Soliman, Michael M. Chen, Byron Padilla, Alan Kivitz
Formato:	Artigo
Idioma:	Inglês
Publicado em:	Adis, Springer Healthcare 2024-03-01
coleção:	Rheumatology and Therapy
Assuntos:	bDMARD-IR csDMARD-IR IL-23 KEEPsAKE 2 Long-term treatment Psoriatic arthritis
Acesso em linha:	https://doi.org/10.1007/s40744-024-00657-2
Tags:	Adicionar Tag Sem tags, seja o primeiro a adicionar uma tag!